Beam Therapeutics Inc. Quarterly Net Cash Provided by (Used in) Financing Activities in USD from Q1 2019 to Q1 2024

Taxonomy & unit
us-gaap: USD
Description
Amount of cash inflow (outflow) from financing activities, including discontinued operations. Financing activity cash flows include obtaining resources from owners and providing them with a return on, and a return of, their investment; borrowing money and repaying amounts borrowed, or settling the obligation; and obtaining and paying for other resources obtained from creditors on long-term credit.
Summary
Beam Therapeutics Inc. quarterly/annual Net Cash Provided by (Used in) Financing Activities history and growth rate from Q1 2019 to Q1 2024.
  • Beam Therapeutics Inc. Net Cash Provided by (Used in) Financing Activities for the quarter ending March 31, 2024 was $2.9M, a 97.1% decline year-over-year.
  • Beam Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2023 was $276M, a 148% increase from 2022.
  • Beam Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2022 was $112M, a 85.2% decline from 2021.
  • Beam Therapeutics Inc. annual Net Cash Provided by (Used in) Financing Activities for 2021 was $756M, a 135% increase from 2020.
Net Cash Provided by (Used in) Financing Activities, Quarterly (USD)
Net Cash Provided by (Used in) Financing Activities, YoY Quarterly Growth (%)
Period TTM Value Value YoY Chg Change % Start Date End Date Report Filed
Q1 2024 $2.9M -$95.5M -97.1% Jan 1, 2024 Mar 31, 2024 10-Q 2024-05-07
Q1 2023 $98.4M +$42.7M +76.8% Jan 1, 2023 Mar 31, 2023 10-Q 2024-05-07
Q1 2022 $55.7M -$198M -78% Jan 1, 2022 Mar 31, 2022 10-Q 2023-05-10
Q1 2021 $253M +$60.3M +31.2% Jan 1, 2021 Mar 31, 2021 10-Q 2022-05-09
Q1 2020 $193M +$155M +409% Jan 1, 2020 Mar 31, 2020 10-Q 2021-05-11
Q1 2019 $37.9M Jan 1, 2019 Mar 31, 2019 10-Q 2020-05-12
* An asterisk sign (*) next to the value indicates that the value is likely invalid.